Natera Highlights New Signatera Genome Assay Data At ESMO 2026, With ctDNA Dynamics Predictive Of Survival Outcomes In Bladder Cancer
Natera’s oncology portfolio featured in 25 ESMO abstracts including 9 oral presentations, with publications in Nature Medicine and ESMO OpenNatera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision
Natera showed new cancer test data at a big science conference. Scientists found the test helps predict how patients might do.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.